Tous les communiqués de presse

- Valbiotis presents the full results of the Phase II/III REVERSE-IT study : impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes, a first for a non-drug active substance.

Voir le communiqué de presse

- First-half 2023 consolidated turnover (IN FRENCH).

Voir le communiqué de presse

- Deeptech start-up and mission oriented company, Oncosema is the winner of the I-LAB Innovation competition (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member.

Voir le communiqué de presse

- Press Kit- The Limagrain wheat industry (IN FRENCH).

Voir le communiqué de presse

- METabolic EXplorer publishes its Sustainability 2022 report (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.

Voir le communiqué de presse

- Q1 2003 Financial Information (IN FRENCH).

Voir le communiqué de presse

- Limagrain starts its recruitment campaign! 600 seasonal crops are expected for its summer and autumn harvests (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces its Combined Shareholders General Meeting will be held on May 2, 2023.

Voir le communiqué de presse